{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:31:09Z","timestamp":1789140669831,"version":"build-2803163510"},"reference-count":42,"publisher":"Oceanside Publications Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Chronic rhinosinusitis is one of the most common medical conditions seen in the U.S. population. Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults has predominately a type 2 inflammatory endotype that usually is treated with medical management that consists\n of inhaled corticosteroids, saline solution irrigation, oral corticosteroid bursts, and, at times, leukotriene antagonists and antibiotics. If medical management fails, then surgical intervention is usually recommended. Various biologics that target type 2 inflammation are now available, which\n have been or will be approved for use in these patients.  <jats:bold>Objective:<\/jats:bold> To determine where biologics that affect the type 2 pathway fit into the algorithm of treatment for CRSwNP.  <jats:bold>Methods:<\/jats:bold> A review of the literature on standard-of-care measures and surgical\n interventions in CRSwNP and an analysis of recent studies on the efficacy and safety of biologics in this condition.  <jats:bold>Results:<\/jats:bold> Standard of care with medication and surgical interventions fail in some patients with CRSwNP. Biologics that affect the type 2 inflammatory pathway\n led to a decrease in nasal polyp size, improved nasal congestion, and improved quality of life both in patients who had surgery and those who had not had surgery for CRSwNP. Also, they showed efficacy and safety in patients whether or not they had comorbid asthma. These agents do not cure\n the patient with CRSwNP, and will be required chronically for control.  <jats:bold>Conclusion:<\/jats:bold> Shared decision-making should be used in determining the use of certain medications, surgical management, and biologics in patients with CRSwNP. In patients for whom surgery has already failed\n and in patients with moderate-to-severe CRSwNP who have other type 2 comorbidities, e.g., asthma, a trial of biologics is a rational course.<\/jats:p>","DOI":"10.2500\/aap.2020.41.200069","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T05:00:37Z","timestamp":1603861237000},"page":"413-419","source":"Crossref","is-referenced-by-count":10,"title":["Chronic rhinosinusitis with nasal polyps management in the age of biologics"],"prefix":"10.2500","volume":"41","author":[{"given":"Michael S.","family":"Blaiss","sequence":"first","affiliation":[{"name":"From the Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1939-4551-7-25","article-title":"ICON: chronic rhinosinusitis","volume":"7","author":"Bachert","year":"2014","journal-title":"World Allergy Organ J"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jaci.2018.12.986","article-title":"Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology","volume":"143","author":"Dietz de Loos","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhino50E2","article-title":"EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists","volume":"50","author":"Fokkens","year":"2012","journal-title":"Rhinology"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaip.2018.10.014","article-title":"Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting","volume":"7","author":"Benjamin","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jaci.2016.06.063","article-title":"Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois","volume":"139","author":"Tan","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.anai.2018.10.014","article-title":"Pathophysiologic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes","volume":"122","author":"Cao","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jaci.2014.08.031","article-title":"Increased noneosinophilic nasal polyps in chronic rhinosinusitis in US second-generation Asians suggest genetic regulation of eosinophilia","volume":"135","author":"Mahdavinia","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/lary.27852","article-title":"Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps","volume":"129","author":"Bhattacharyya","year":"2019","journal-title":"Laryngoscope"},{"key":"B9","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.anai.2018.09.061","article-title":"Impact of chronic rhinosinusitis with nasal polyposis on quality of life by sino-nasal surgery history","volume":"121","author":"Khan","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/alr.21315","article-title":"The fate of chronic rhinosinusitis sufferers after maximal medical therapy","volume":"4","author":"Baguley","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.anai.2014.07.025","article-title":"Diagnosis and management of rhinosinusitis: a practice parameter update","volume":"113","author":"Peters","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B12","first-page":"CD011993","article-title":"Different types of intranasal steroids for chronic rhinosinusitis","volume":"4","author":"Chong","year":"2016","journal-title":"Cochrane database Syst Rev"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jaci.2005.07.027","article-title":"Efficacy and safety of mometasone furoate nasal spray in nasal polyposis","volume":"116","author":"Small","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaci.2018.06.010","article-title":"NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis","volume":"143","author":"Leopold","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/alr.22093","article-title":"Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery","volume":"8","author":"Harvey","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"B16","first-page":"CD011992","article-title":"Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis","volume":"4","author":"Head","year":"2016","journal-title":"Cochrane database Syst Rev"},{"key":"B17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"B18","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/alr.21416","article-title":"Safety, feasibility, and efficacy of placement of steroid-eluting bioabsorbable sinus implants in the office setting: a prospective case series","volume":"4","author":"Matheny","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/alr.22084","article-title":"A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps","volume":"8","author":"Kern","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1398-9995.2011.02693.x","article-title":"Lack of efficacy of long-term, low-dose azithromycin in chronic rhinosinusitis: a randomized controlled trial","volume":"66","author":"Videler","year":"2011","journal-title":"Allergy"},{"key":"B21","article-title":"Systemic and topical antibiotics for chronic rhinosinusitis","volume":"4:CD011994","author":"Head","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B22","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/alr.22338","article-title":"Topical antibiotic therapy in chronic rhinosinusitis: an update","volume":"9","author":"Carlton","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.plefa.2017.09.009","article-title":"The role of cysteinyl leukotrienes and their receptors in refractory nasal polyps","volume":"126","author":"Du","year":"2017","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"key":"B24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2500\/ajra.2013.27.3976","article-title":"Leukotriene antagonists in nasal polyposis: a meta-analysis and systematic review","volume":"27","author":"Wentzel","year":"2013","journal-title":"Am J Rhinol Allergy"},{"key":"B25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.otc.2005.07.003","article-title":"Maximal medical therapy for chronic rhinosinusitis","volume":"38","author":"Lund","year":"2005","journal-title":"Otolaryngol Clin North Am"},{"key":"B26","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.2500\/ar.2012.3.0027","article-title":"Efficacy of medical therapy in treatment of chronic rhinosinusitis","volume":"3","author":"Young","year":"2012","journal-title":"Allergy Rhinol (Providence)"},{"key":"B27","first-page":"S22","article-title":"International Consensus Statement on Allergy and Rhinology: rhinosinusitis","volume":"6","author":"Orlandi","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"B28","first-page":"S64","article-title":"Comprehensive review on endonasal endoscopic sinus surgery","volume":"94","author":"Weber","year":"2015","journal-title":"Laryngorhinootologie"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jaci.2018.03.004","article-title":"Endotype-driven care pathways in patients with chronic rhinosinusitis","volume":"141","author":"Bachert","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13601-019-0269-4","article-title":"Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis","volume":"9","author":"Calus","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"B31","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/lary.27815","article-title":"Endoscopic sinus surgery for type-2 CRS wNP: an endotype-based retrospective study","volume":"129","author":"Alsharif","year":"2019","journal-title":"Laryngoscope"},{"key":"B32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.anai.2018.08.019","article-title":"Shared decision making for the allergist","volume":"122","author":"Blaiss","year":"2019","journal-title":"Ann Allergy, Asthma Immunol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.7326\/0003-4819-136-2-200201150-00010","article-title":"Health decision aids to facilitate shared decision making in office practice","volume":"136","author":"Barry","year":"2002","journal-title":"Ann Intern Med"},{"key":"B38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/lary.25180","article-title":"Cost of adult chronic rhinosinusitis: a systematic review","volume":"125","author":"Smith","year":"2015","journal-title":"Laryngoscope"},{"key":"B39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/lary.24916","article-title":"Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis","volume":"125","author":"Rudmik","year":"2015","journal-title":"Laryngoscope"},{"key":"B40","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1525-1497.1998.00211.x","article-title":"Interpretation of cost-effectiveness analyses","volume":"13","author":"Owens","year":"1998","journal-title":"J Gen Intern Med"},{"key":"B41","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.anai.2019.07.004","article-title":"A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps","volume":"123","author":"Codispoti","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?","volume":"122","author":"Anderson","year":"2019","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2020\/00000041\/00000006\/art00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T05:28:53Z","timestamp":1604726933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2020.41.200069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["1088-5412(20201101)41:6L.413;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2020.41.200069","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}